Zoetis Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 35 rows in 2023. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2023-11-21: Reporting owner PECK KRISTIN C; Form 4; Security Stock Option; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2023-11-21: Reporting owner PECK KRISTIN C; Form 4; Security Stock Option; Transaction Holding.
- 2023-08-22: Reporting owner PECK KRISTIN C; Form 4; Security Stock Option; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2023-08-22: Reporting owner PECK KRISTIN C; Form 4; Security Stock Option; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2023-11-21 | PECK KRISTIN C Director, Officer (Chief Executive Officer) | 4 | Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,000 283,014 owned after | $0.00 | $178.73 | 2023-11-21 |
| 2023-11-21 holding as of filing | PECK KRISTIN C Director, Officer (Chief Executive Officer) | 4 | Stock Option Derivative · Direct | Holding | 67,148 owned after | $162.07 exercise price | 2023-11-21 | |
| 2023-08-22 | PECK KRISTIN C Director, Officer (Chief Executive Officer) | 4 | Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,250 306,764 owned after | $0.00 | $181.82 | 2023-08-22 |
| 2023-08-22 | PECK KRISTIN C Director, Officer (Chief Executive Officer) | 4 | Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,750 296,014 owned after | $0.00 | $181.82 | 2023-08-22 |
| 2023-08-22 holding as of filing | PECK KRISTIN C Director, Officer (Chief Executive Officer) | 4 | Stock Option Derivative · Direct | Holding | 67,148 owned after | $162.07 exercise price | 2023-08-22 | |
| 2023-08-11 holding as of filing | Polzer Robert J Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | Holding | 7,260 owned after | $162.07 exercise price | 2023-08-11 | |
| 2023-08-09 | Polzer Robert J Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,179 6,512 owned after | $0.00 | $189.35 | 2023-08-11 |
| 2023-05-25 holding as of filing | PECK KRISTIN C Director, Officer (Chief Executive Officer) | 4 | Stock Option Derivative · Direct | Holding | 67,148 owned after | $162.07 exercise price | 2023-05-25 | |
| 2023-05-23 | PECK KRISTIN C Director, Officer (Chief Executive Officer) | 4 | Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,000 309,014 owned after | $0.00 | $172.67 | 2023-05-25 |
| 2023-04-19 holding as of filing | Lagano Roxanne Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | Holding | 6,542 owned after | $162.07 exercise price | 2023-04-19 | |
| 2023-04-18 | Lagano Roxanne Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,328 22,231 owned after | $0.00 | $174.45 | 2023-04-19 |
| 2023-04-18 | Lagano Roxanne Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,010 20,221 owned after | $0.00 | $174.45 | 2023-04-19 |
| 2023-02-16 holding as of filing | Lagano Roxanne Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | Holding | 6,542 owned after | $162.07 exercise price | 2023-02-16 | |
| 2023-02-14 | Lagano Roxanne Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,984 30,585 owned after | $0.00 | $171.90 | 2023-02-16 |
| 2023-02-14 | Lagano Roxanne Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,026 24,559 owned after | $0.00 | $171.90 | 2023-02-16 |
| 2023-02-10 holding as of filing | Polzer Robert J Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | Holding | 7,691 owned after | no price filed | 2023-02-10 | |
| 2023-02-10 holding as of filing | PECK KRISTIN C Director, Officer (Chief Executive Officer) | 4 | Stock Option Derivative · Direct | Holding | 322,014 owned after | no price filed | 2023-02-10 | |
| 2023-02-10 holding as of filing | Mamilli Wafaa Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | Holding | 28,607 owned after | no price filed | 2023-02-10 | |
| 2023-02-10 holding as of filing | Lagano Roxanne Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | Holding | 37,569 owned after | no price filed | 2023-02-10 | |
| 2023-02-10 holding as of filing | Joseph Wetteny Officer (Chief Financial Officer) | 4 | Stock Option Derivative · Direct | Holding | 11,243 owned after | no price filed | 2023-02-10 | |
| 2023-02-10 holding as of filing | Ferran Astorga Jeannette Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | Holding | 4,057 owned after | no price filed | 2023-02-10 | |
| 2023-02-10 holding as of filing | Driscoll Rimma Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | Holding | 5,271 owned after | no price filed | 2023-02-10 | |
| 2023-02-10 holding as of filing | Chen Heidi C. Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | Holding | 39,737 owned after | no price filed | 2023-02-10 | |
| 2023-02-10 holding as of filing | Brannan Jamie Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | Holding | 6,941 owned after | no price filed | 2023-02-10 | |
| 2023-02-10 holding as of filing | Ashton Nicholas Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | Holding | 3,369 owned after | no price filed | 2023-02-10 | |
| 2023-02-08 | Polzer Robert J Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,260 7,260 owned after | $162.07 exercise price | $162.07 | 2023-02-10 |
| 2023-02-08 | PECK KRISTIN C Director, Officer (Chief Executive Officer) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +67,148 67,148 owned after | $162.07 exercise price | $162.07 | 2023-02-10 |
| 2023-02-08 | Mamilli Wafaa Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,633 7,633 owned after | $162.07 exercise price | $162.07 | 2023-02-10 |
| 2023-02-08 | Lagano Roxanne Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,542 6,542 owned after | $162.07 exercise price | $162.07 | 2023-02-10 |
| 2023-02-08 | Joseph Wetteny Officer (Chief Financial Officer) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,208 15,208 owned after | $162.07 exercise price | $162.07 | 2023-02-10 |
| 2023-02-08 | Ferran Astorga Jeannette Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +2,353 2,353 owned after | $162.07 exercise price | $162.07 | 2023-02-10 |
| 2023-02-08 | Driscoll Rimma Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +2,077 2,077 owned after | $162.07 exercise price | $162.07 | 2023-02-10 |
| 2023-02-08 | Chen Heidi C. Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,834 7,834 owned after | $162.07 exercise price | $162.07 | 2023-02-10 |
| 2023-02-08 | Brannan Jamie Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,103 4,103 owned after | $162.07 exercise price | $162.07 | 2023-02-10 |
| 2023-02-08 | Ashton Nicholas Officer (Executive Vice President) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,304 4,304 owned after | $162.07 exercise price | $162.07 | 2023-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |